Zacks Investment Research·Jun 29, 2026
RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared ToolsRadNet's DeepHealth gains FDA clearances for AI breast imaging tools that assess cardiovascular risk and compare prior mammograms.
RadNet, Inc.(RDNT)Earnings, Financials & Key Ratios
RDNT•NASDAQ
$67.83
Price updated Jul 7, 2026
AboutRadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.Show more
- Revenue$2.04B+11.5%
- EBITDA$243M+0.2%
- Net Income-$19M-767.8%
- EPS (Diluted)-0.25-768.4%
- Gross Margin4.45%-67.3%
- EBITDA Margin11.91%-10.1%
- Operating Margin4.45%-22.2%
- Net Margin-0.91%-698.7%
- ROE-1.5%-622.3%
RDNT Price & Volume
RadNet, Inc. (RDNT) stock price & volume — 10-year historical chart
Loading chart...
Aggressive Inorganic Expansion Pressures Operational Profitability Metrics
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Accelerating
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Margin volatility and scale
Key Thesis Takeaways
- RadNet is pursuing an aggressive growth-at-any-cost strategy characterized by heavy debt-funded acquisitions and significant capital expenditure, which has resulted in a $303.9 million net acquisition outflow in 2026Q1.
- While top-line revenue growth remains robust at 22.1%, the company faces structural challenges in achieving economies of scale, as evidenced by a negative 2.8% operating margin.
- Investors should monitor the sustainability of this model, given the $128.9 million deficit in retained earnings and the persistent volatility in free cash flow margins.
Verdict Logic
the company's inability to maintain positive net margins, evidenced by a -5.8% net margin in 2026Q1, suggests significant execution risk regarding the long-term viability of its current inorganic growth model.
RDNT Growth Metrics
RadNet, Inc. (RDNT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.68%
5 Years13.74%
3 Years12.57%
TTM14.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.32%
Return on Capital
10 Years4.57%
5 Years3.95%
3 Years3.95%
Last Year3.04%
RDNT Recent Earnings
RadNet, Inc. (RDNT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.28-100.0%
$0.14
Rev
$576M+3.2%
$558M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.23+21.1%
$0.19
Rev
$548M+6.0%
$517M
Q4 2025
Nov 9, 2025Metric
Actual
Est
EPS
$0.20-10.3%
$0.22
Rev
$523M+5.7%
$494M
Q3 2025
Aug 10, 2025Metric
Actual
Est
EPS
$0.31+82.4%
$0.17
Rev
$498M+1.0%
$494M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.28vs $0.14-100.0% | $576Mvs $558M+3.2% |
| Q2 2026 | Mar 2, 2026 | $0.23vs $0.19+21.1% | $548Mvs $517M+6.0% |
| Q4 2025 | Nov 9, 2025 | $0.20vs $0.22-10.3% | $523Mvs $494M+5.7% |
| Q3 2025 | Aug 10, 2025 | $0.31vs $0.17+82.4% | $498Mvs $494M+1.0% |
Based on last 12 quarters of dataView full earnings history →
Latest RDNT News
Recent stock market news and headlines for RadNet, Inc. (RDNT)
GlobeNewsWire·Jun 25, 2026
DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast SuiteSOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), announces it has received FDA 510(k) clearances for two new Breast Suite1 functionalities: Breast Arterial Calcification (BAC) Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease;2 Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducing recalls.
GuruFocus·Jun 22, 2026
RadNet Inc (RDNT) Stock Up 3.8% and Still Undervalued -- GF Score: 79/100On June 22, 2026, RadNet Inc (RDNT) shares rose 3.8% today, trading at $55.74. The stock has experienced a 52-week range of $50.76 to $85.84, reflecting volatil
Peers Comparison
Key metrics vs top competitors for RadNet, Inc. (RDNT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $67.83 | $5.33B | -271.32 | 11.51% | -0.91% | -1.5% | — | |
| $29.44 | $156.22M | 12.47 | 19.03% | 11.39% | 19.91% | — | |
| $71.80 | $1.09B | 50.56 | 16.33% | 1.52% | 1.36% | — | |
| $35.45 | $663.05M | 14.35 | 2.63% | 14.27% | 17.85% | — | |
| $24.46 | $1.19B | 116.48 | 13.59% | 2.55% | 2.66% | — | |
| $161.26 | $10.09B | 6.98 | 9.71% | 8.56% | 20.65% | — |
Compare RDNT vs Peers
RadNet, Inc. (RDNT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RDNT SEC Filings & Documents
RadNet, Inc. (RDNT) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Mar 2, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when RDNT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RDNT Frequently Asked Questions
RadNet, Inc. (RDNT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is RadNet, Inc.'s revenue?
RadNet, Inc. (RDNT) reported $2.14B in revenue for fiscal year 2025. This represents a 3693% increase from $56.5M in 1996.
How fast is RadNet, Inc. growing?
RadNet, Inc. (RDNT) grew revenue by 11.5% over the past year. This is steady growth.
Is RDNT profitable?
RadNet, Inc. (RDNT) reported a net loss of $14.2M for fiscal year 2025.
Dividend & Returns
What is RDNT's return on equity?
RadNet, Inc. (RDNT) has a return on equity (ROE) of -1.5%. Negative ROE indicates the company is unprofitable.
What is RadNet, Inc.'s free cash flow?
RadNet, Inc. (RDNT) had negative free cash flow of $148.7M in fiscal year 2025, likely due to heavy capital investments.